Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial

McAuley, Daniel F.; Cross, L.J.M.; Hamid, Umar Imran; Gardner, Evie; Elborn, J. Stuart; Cullen, Kathy; Dushianthan, Ahilanandan; Grocott, Michael P.W.; Matthay, Michael A.; O'Kane, Cecilia M

doi:10.1016/s2213-2600(17)30171-6

Cited by 74 publications

(54 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, KGF is thought to augment epithelial repair and therefore might improve pulmonary dysfunction in acute respiratory distress syndrome. However, a randomized, placebo-controlled phase 2 trial demonstrated that KGF was not beneficial in the treatment of acute respiratory distress syndrome and might even make clinical outcomes worse [67]. A possible explanation for the low efficacy of KGF in this study is the systemic administration regimen, which cannot directly target the injured lung epithelium.…”

Section: Functional Molecules Expressed or Produced By ‘Repair’ Tregsmentioning

confidence: 90%

‘Repair’ Treg Cells in Tissue Injury

Zhang

Feng

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Studies in mice and humans have elucidated an important role for Tregs in promoting tissue repair and restoring tissue integrity. Emerging evidence has revealed that Tregs promoted wound healing and repair processes at multiple tissue sites, such as the heart, liver, kidney, muscle, lung, bone and central nervous system. The localization of repair Tregs in the lung, muscle and liver exhibited unique phenotypes and functions. Epidermal growth factor receptor, amphiregulin, CD73/CD39 and keratinocyte growth factor are important repair factors that are produced or expressed by repair Tregs; these factors coordinate with parenchymal cells to limit injury and promote repair. In addition, repair Tregs can be modulated by IL-33/ST2, TCR signals and other cytokines in the context of injured microenvironment cues. In this review, we provide an overview of the emerging knowledge about Treg-mediated repair in damaged tissues and organs.

show abstract

Section: Functional Molecules Expressed or Produced By ‘Repair’ Tregsmentioning

confidence: 90%

‘Repair’ Treg Cells in Tissue Injury

Zhang

Feng

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…The ex vivo-perfused human lung can be useful for testing novel therapeutics in acute lung injury and has laid the groundwork for some clinical trials in lung donor management (45) and cell-based therapy for the treatment of acute lung injury (46,47). Examples of therapeutics tested in the ex vivo-perfused human lung are described in Table 3.…”

Section: Ex Vivo-perfused Human Lung: a Therapeutic-testing Platformmentioning

confidence: 99%

The ex vivo human lung: research value for translational science

Ross¹,

Nesseler²,

Lee³

et al. 2019

JCI Insight

View full text Add to dashboard Cite

“…Unauthorized reproduction of this article is prohibited. (3,11) 11 (6,18) < 0.001 Ventilator-free days, median (IQR), days 22 (6,25) 9 (0, 20) < 0.001 ICU length of stay, median (IQR), days 9 (5,17) 14 (8,22) < 0.001 ICU mortality, No. (%) 53 (16.9) 89 (33.3) < 0.001 Hospital length of stay, median (IQR), days 20 (11,38) 19 (11,37) 0.950 Hospital mortality, No.…”

Section: Population Definitionmentioning

confidence: 99%

Outcomes of Patients Presenting with Mild Acute Respiratory Distress Syndrome

Pham¹,

Neto²,

Pelosi³

et al. 2019

Anesthesiology

View full text Add to dashboard Cite

T HE Berlin definition of acute respiratory distress syndrome (ARDS) categorizes patients with partial pressure of arterial blood oxygen content to inspired fraction of oxygen (PaO 2 /fraction of inspired oxygen [FIO 2 ]) ranging from 200 to 300 mmHg as "mild ARDS." 1 In the preceding American European Consensus Conference, this population was defined as having "non-ARDS acute lung injury." 2 Some clinicians continue to overlook these less severely hypoxemic patients and instead pay closer attention to patients they consider to have "actual" ARDS (i.e., moderate and severe ARDS groups). This group has not been included in some recent studies recruiting patients with ARDS. 3-6 Patients Editor's Perspective What We Already Know about This Topic • Hospital mortality in acute respiratory distress syndrome is approximately 40%, but mortality and trajectory in "mild" acute respiratory distress syndrome (classified only since 2012) are unknown, and many cases are not detected What This Article Tells Us That Is New • Approximately 80% of cases of mild acute respiratory distress syndrome persist or worsen in the first week; in all cases, the mortality is substantial (30%) and is higher (37%) in those in whom the acute respiratory distress syndrome progresses

show abstract

Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial

Cited by 74 publications

References 49 publications

‘Repair’ Treg Cells in Tissue Injury

‘Repair’ Treg Cells in Tissue Injury

The ex vivo human lung: research value for translational science

Outcomes of Patients Presenting with Mild Acute Respiratory Distress Syndrome

Contact Info

Product

Resources

About